New injection aims to improve breathing in COPD patients
NCT ID NCT07519499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called XKH001 in 75 people with moderate to severe COPD. The drug is given as an injection to see if it can improve lung function and reduce symptoms over 24 to 48 weeks. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doctors will know which they receive. The goal is to find a new way to manage COPD and help people breathe easier.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may curb antibiotic overuse in COPD attacks
- Can pressurized breathing boost mucus clearance in lung disease?
- HIV and hidden health risks: a major study probes the link
- Can tracking early COPD reveal ways to halt its progression?
- Smart inhaler coach: can an app perfect your breathing technique?
- Could everyday supplements shield your lungs?